Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.remnie.2022.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients.
Transplant Cell Ther
October 2024
Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Montréal, Québec, Canada; Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Article Synopsis
- Multiple myeloma (MM) poses significant treatment challenges, particularly for high-risk patients, with allogeneic hematopoietic cell transplantation (HCT) often resulting in severe side effects and high mortality rates.
- This study investigates the safety and feasibility of using UM171-expanded cord blood transplantation combined with autologous HCT for patients with high-risk MM.
- Out of 20 enrolled patients, 19 successfully underwent the UM171 procedure, highlighting potential improvements in patient outcomes despite the historical issues associated with cord blood transplantation.
Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis.
Therapie
November 2024
Department of Pharmacology, Regional Pharmacovigilance Center Pitié-Saint-Antoine, Pitié-Salpêtrière Hospital, 75000 Paris, France. Electronic address:
Article Synopsis
- The study examines the impact of COVID-19 vaccination safety reports on adverse reaction signal detection in pharmacovigilance databases like VigiBase, showing that July 2022 reports accounted for over 10% of total cases.
- It utilized the Information Component (IC) to analyze the relationship between reported adverse effects and COVID-19 vaccines by comparing a group of reports including vaccine cases (V+) to a group excluding them (V-).
- The results indicated a significant difference in potential signal detection, with "unexpected" adverse reactions losing signals when vaccine reports were excluded, while "expected" reactions often displayed new signals in the absence of those reports.
Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic.
AIDS
April 2024
Laboratoire de Pharmacologie-Toxicologie, Pharmacovigilance & Centre d'évaluation et d'information sur la Pharmacodépendance-Addictovigilance, Centre Hospitalier Régional et Universitaire de Nancy Brabois, Bâtiment de Biologie Médicale et de Biopathologie, Vandœuvre-Lès-Nancy.
Due to the start of the monkeypox epidemic in 2022, we retrospectively analyzed the adverse drug reactions (ADRs) reported in France after monkeypox vaccinations with the third-generation smallpox vaccine. Ninety-eight cases, representing 172 ADRs, were reported. ADRs were mostly expected reactogenicity reactions occurring within days after the first dose of vaccine and having a quick favorable outcome.
View Article and Find Full Text PDFDurability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Open Forum Infect Dis
December 2023
Unité de prise en charge du VIH, Hôpital de District de la Cité Verte, Yaoundé, Cameroon.
Article Synopsis
- The NAMSAL-ANRS-12313 trial compared the efficacy of dolutegravir (DTG) versus efavirenz (EFV400) in treating HIV in low-income countries over a 96-week period, demonstrating DTG's noninferiority and continued effectiveness at 192 weeks.
- At week 192, viral suppression remained higher in participants on the DTG regimen (69%) compared to those on EFV400 (62%), with slight differences in new viral failures and serious adverse events noted between the two groups.
- Both treatment groups experienced significant weight gain, with participants on DTG/TDF/3TC gaining an average of 9.4 kg and an increase in obesity prevalence, raising concerns about
rtPA-loaded fucoidan polymer microbubbles for the targeted treatment of stroke.
Biomaterials
December 2023
Université Paris Cité, Université Sorbonne Paris Nord, UMR-S U1148 INSERM, Laboratory for Vascular Translational Science (LVTS), F-75018, Paris, France. Electronic address:
Systemic injection of thrombolytic drugs is the gold standard treatment for non-invasive blood clot resolution. The most serious risks associated with the intravenous injection of tissue plasminogen activator-like proteins are the bleeding complication and the dose related neurotoxicity. Indeed, the drug has to be injected in high concentrations due to its short half-life, the presence of its natural blood inhibitor (PAI-1) and the fast hepatic clearance (0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!